AnaCardio raises USD 19 million to advance first-in-class drug candidate AC01 for heart failure
Reports positive results from phase 1b study of AC01 in patients with heart failure and reduced ejection fraction (HFrEF) January 9, 2025, Stockholm, Sweden – AnaCardio, a clinical-stage biopharmaceutical company developing novel contractile agents to treat patients with heart failure today announced the completion of a USD 19 million (SEK 205 million) Series A extension […]